Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on

Neuroscience and Biobehavioral Reviews

Volumn 29, Issue 8, 2005, Pages 1193-1205

  Carobrez, A P ^a   Bertoglio, L J ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal models; Anxiety; Min by min scoring; Risk assessment; Test retest protocol

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; ALCOHOL; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CHLORDIAZEPOXIDE; DIAZEPAM; DIZOCILPINE; MEMANTINE; MIDAZOLAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PENTETRAZOLE; PHENOBARBITAL; SCOPOLAMINE;

ANXIETY DISORDER; AVERSIVE BEHAVIOR; BEHAVIORAL SCIENCE; CONFERENCE PAPER; DEFENSE MECHANISM; DNA MODIFICATION; DRUG EFFECT; EMOTION; ETHOLOGY; LEARNING DISORDER; LOW DRUG DOSE; MAZE TEST; METHODOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; RODENT; SCORING SYSTEM; VALIDATION PROCESS;

AGGRESSION; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; ETHOLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; MAZE LEARNING; MODELS, BIOLOGICAL;

EID: 26844489352     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2005.04.017     Document Type: Conference Paper

References (153)

1. R.E. Adamec, and T. Shallow Lasting effects on rodent anxiety of a single exposure to a cat Physiol. Behav. 54 1993 101 109
2. R. Adamec, and T. Shallow Effects of baseline anxiety on response to kindling of the right medial amygdala Physiol. Behav. 70 2000 67 80
3. R. Adamec, and B. Young Neuroplasticity in specific limbic system circuits may mediate specific kindling induced changes in animal affect-implications for understanding anxiety associated with epilepsy Neurosci. Biobehav. Rev. 24 2000 705 723
4. R. Adamec, P. Kent, H. Anisman, T. Shallow, and Z. Merali Neural plasticity, neuropeptides and anxiety in animals-implications for understanding and treating affective disorder following traumatic stress in humans Neurosci. Biobehav. Rev. 23 1998 301 318
5. R.E. Adamec, P. Burton, T. Shallow, and J. Budgell Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle - effective hemisphere depends on the behavior Physiol. Behav. 65 1999 739 751
6. R.E. Adamec, J. Blundell, and A. Collins Neural plasticity and stress induced changes in defense in the rat Neurosci. Biobehav. Rev. 25 2001 721 744
7. R.E. Adamec, J. Blundell, and P. Burton Phosphorylated cyclic AMP response element binding protein expression induced in the periaqueductal gray by predator stress: its relationship to the stress experience, behavior and limbic neural plasticity Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1243 1267
8. S.S. Almeida, R.A. Garcia, and L.M. DeOliveira Effects of early protein malnutrition and repeated testing upon locomotor and exploratory behaviors in the elevated plus-maze Physiol. Behav. 54 1993 749 752
9. I.L. Andersen, K.E. Boe, G. Foerevik, A.M. Janczak, and M. Bakken Behavioural evaluation of methods for assessing fear responses in weaned pigs Appl. Anim. Behav. Sci. 69 2000 227 240
10. T.G. Andrade, A.M. Silva, C.L. Silva, and F.G. Graeff Effect of electrolytic lesion of the median raphe nucleus on behavioral and physiological measures of stress Acta Physiol. Pharmacol. Ther. Latinoam. 49 1999 279 289
11. M.M. Andrade, M.F. Tome, E.S. Santiago, A. Lucia-Santos, and T.G. de Andrade Longitudinal study of daily variation of rats' behavior in the elevated plus-maze Physiol. Behav. 78 2003 125 133
12. R. Andreatini, M.A.B.F. Vital, and G.L. Santos The reinstatement of conflict reverses the one-trial tolerance to diazepam on elevated plus-maze Eur. Neuropsychopharmacol. 13 Suppl. 4 2003 S378 S379
13. N. Andrews, and S.E. File Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety Eur. J. Pharmacol. 235 1993 109 112
14. V.Z. Anseloni, V. Motta, G. Lima, and M.L. Brandão Behavioral and pharmacological validation of the elevated plus maze constructed with transparent walls Braz. J. Med. Biol. Res. 28 1995 597 601
15. S.V. Argyropoulos, J.J. Sandford, and D.J. Nutt The psychobiology of anxiolytic drug. Part 2: pharmacological treatments of anxiety Pharmacol. Ther. 88 2000 213 227
16. D.M. Bannerman, J.N. Rawlins, S.B. McHugh, R.M. Deacon, B.K. Yee, T. Bast, W.N. Zhang, H.H. Pothuizen, and J. Feldon Regional dissociations within the hippocampus - memory and anxiety Neurosci. Biobehav. Rev. 28 2004 273 283
17. S.R. Beckett, M.S. Duxon, S. Aspley, and C.A. Marsden Central c-fos expression following 20kHz/ultrasound induced defence behaviour in the rat Brain Res. Bull. 42 1997 421 426
18. C. Belzung Measuring rodent exploratory behavior W.E. Crusio R.T. Gerlai Handbook of Molecular Genetic Techniques for Brain and Behavior Research Techniques in the Behavioral and Neural Sciences 1999 Elsevier Amsterdam 738 749
19. C. Belzung, and G. Griebel Measuring normal and pathological anxiety-like behaviour in mice: a review Behav. Brain Res. 125 2001 141 149
20. V. Bergink, H.J. van Megen, and H.G. Westenberg Glutamate and anxiety Eur. Neuropsychopharmacol. 14 2004 175 183
21. L.J. Bertoglio, and A.P. Carobrez Previous maze experience required to increase open arm avoidance in rats submitted to the elevated plus-maze model of anxiety Behav. Brain Res. 108 2000 197 203
22. L.J. Bertoglio, and A.P. Carobrez Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus maze Pharmacol. Biochem. Behav. 73 2002 963 969
23. L.J. Bertoglio, and A.P. Carobrez Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions Behav. Brain Res. 132 2002 135 143
24. L.J. Bertoglio, and A.P. Carobrez Prior maze experience required to alter midazolam effects in rats submitted to the elevated plus-maze Pharmacol. Biochem. Behav. 72 2002 449 455
25. L.J. Bertoglio, and A.P. Carobrez Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze Trial 2 in rats Psychopharmacology 170 2003 335 342
26. L.J. Bertoglio, and A.P. Carobrez Scopolamine given pre-Trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze Trial 2 Behav. Pharmacol. 15 2004 45 54
27. L.J. Bertoglio, M. Patel, M.J. Caron, and A.P. Carobrez Rats previously experienced in the elevated plus-maze test no longer display an anxiolytic-like effect in response to 8-OH-DPAT, an agonist of the 5-HT1a receptors Annals of XXXVI Congresso Brasileiro de Farmacologia e Terapêutica Experimental, pp 2004 147
28. Bertoglio, L.J., Anzini, C., Lino-de-Oliveira, C., Carobrez, A.P., 2005. Enhanced dorsolateral periaqueductal gray activity counteracts the anxiolytic response to midazolam on the elevated plus-maze Trial 2 in rats. Behav. Brain Res. 162, 99-107.
29. R.J. Blanchard, and D.C. Blanchard Antipredator defensive behaviors in a visible burrow system J. Comp. Psychol. 103 1989 70 82
30. D.C. Blanchard, R.J. Blanchard, and R.J. Rodgers Risk assessment and animal models of anxiety B. Olivier J. Mos J.L. Slangen Animal models in Psychopharmacology 1991 Basel Birkauser 117 134
31. R.J. Blanchard, E.B. Yudko, R.J. Rodgers, and D.C. Blanchard Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety Behav. Brain Res. 58 1993 155 165
32. R. Boerngen-Lacerda, and M.L. Souza-Formigoni Does the increase in locomotion induced by ethanol indicate its stimulant or anxiolytic properties? Pharmacol. Biochem. Behav. 67 2000 225 232
33. P. Boguszewski, and J. Zagrodzka Emotional changes related to age in rats - a behavioral analysis Behav. Brain Res. 133 2002 323 332
34. F. Borsini, J. Podhorna, and D. Marazziti Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163 2002 121 141
35. R.R. Brett, and J.A. Pratt Chronic handling modifies the anxiolytic effect of diazepam in the elevated plus-maze Eur. J. Pharmacol. 178 1990 135 138
36. F. Calatayud, C. Belzung, and A. Aubert Ethological validation and the assessment of anxiety-like behaviours: methodological comparison of classical analyses and structural approaches Behav. Process. 67 2004 195 206
37. S. Campeau, W.A. Falls, W.E. Cullinan, D.L. Helmreich, M. Davis, and S.J. Watson Elicitation and reduction of fear: behavioural and neuroendocrine indices and brain induction of the immediate-early gene c-fos Neuroscience 78 1997 1087 1104
38. N.S. Canteras, and M. Goto Fos-like immunoreactivity in the periaqueductal gray of rats exposed to a natural predator NeuroReport 10 1999 413 418
39. A. Canto-de-Souza, R.L. Nunes-de-Souza, and R.J. Rodgers Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience Brain Res. 928 2002 50 59
40. F. Cardenas, M.R. Lamprea, and S. Morato Vibrissal sense is not the main sensory modality in rat exploratory behavior in the elevated plus-maze Behav. Brain Res. 122 2001 169 174
41. A.P. Carobrez Glutamatergic neurotransmission as molecular target in anxiety Rev. Bras. Psiquiatr. 25 Suppl. 2 2003 52 58
42. A.P. Carobrez, K.V. Teixeira, and F.G. Graeff Modulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor Neurosci. Biobehav. Rev. 25 2001 697 709
43. V. Carola, F. D'Olimpio, E. Brunamonti, F. Mangia, and P. Renzi Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice Behav. Brain Res. 134 2002 49 57
44. Y. Clement, F. Calatayud, and C. Belzung Genetic basis of anxiety-like behaviour: a critical review Brain Res. Bull. 57 2002 57 71
45. J.C. Cole, and R.J. Rodgers An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze Behav. Pharmacol. 4 1993 573 580
46. A.P. Cruz, F. Frei, and F.G. Graeff Ethopharmacological analysis of rat behavior on the elevated plus-maze Pharmacol. Biochem. Behav. 49 1994 171 176
47. S.E. Cruz-Morales, N.R. Santos, and M.L. Brandão One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic-sensitive behaviors in the elevated plus-maze retest in the rat Pharmacol. Biochem. Behav. 72 2002 973 978
48. N.L. Da Silva, V.M. Ferreira, A.de.P. Carobrez, and G.S. Morato Individual housing from rearing modifies the performance of young rats on the elevated plus-maze apparatus Physiol. Behav. 60 1996 1391 1396
49. M.L.C. Dal-Col, L. Orlandi-Pereira, V.P. Rosa, A.V. Calixto, A.P. Carobrez, and M.S. Faria Lack of midazolam-induced anxiolysis in the plus-maze Trial 2 is dependent on the length of Trial 1 Pharmacol. Biochem. Behav. 74 2003 395 400
50. G.R. Dawson, and M.D. Tricklebank Use of the elevated plus-maze in the search for novel anxiolytic agents Trends Pharmacol. Sci. 16 1995 33 36
51. G.R. Dawson, S.P. Crawford, K.J. Stanhope, S.D. Iversen, and M.D. Tricklebank One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure Psychopharmacology 113 1994 570 572
52. N. De-Mello, and A.P. Carobrez Elevated T-maze as an animal model of memory: effects of scopolamine Behav. Pharmacol. 13 2002 139 148
53. R.A. Dielenberg, G.E. Hunt, and I.S. McGregor When a rat smells a cat: the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor Neuroscience 104 2001 1085 1097
54. C.T. Dourish, S.S. Grewal, J.K. Shepherd, K.J. Stanhope, D.J. Bill, and A. Fletcher Benefits of ethological analysis of behaviour Trends Pharmacol. Sci. 16 1995 260
55. M.D. Escarabajal, C. Torres, and C.F. Flaherty The phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze test is abolished by previous administration of chlordiazepoxide or buspirone Life Sci. 73 2003 1063 1074
56. E.F. Espejo Effects of weekly or daily exposure to the elevated plus-maze in male mice Behav. Brain Res. 87 1997 233 238
57. U. Falter, A.J. Gower, and J. Gobert Resistance of baseline activity in the elevated plus-maze to exogenous influences Behav. Pharmacol. 3 1992 123 128
58. C. Fernandes, and S.E. File The influence of open arm ledges and maze experience in the elevated plus-maze Pharmacol. Biochem. Behav. 54 1996 31 40
59. S.E. File One-trial tolerance to the anxiolytic effect of chlordiazepoxide in the plus-maze Psychopharmacology 100 1990 281 282
60. S.E. File Behavioral detection of anxiolytic action J.M. Elliott D.J. Heal C.A. Marsden Experimental Approaches to Anxiety and Depression 1992 Wiley New York 25 44
61. S.E. File The interplay of learning and anxiety in the elevated plus-maze Behav. Brain Res. 58 1993 199 202
62. S.E. File, and H. Zangrossi Jr 'One-trial tolerance' to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology 110 1993 240 244
63. S.E. File, P.S. Mabbutt, and P.K. Hitchott Characterization of phenomenon of 'one-trial tolerance' to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze Psychopharmacology 102 1990 98 101
64. S.E. File, N. Andrews, P.Y. Wu, A. Zharkovsky, and H. Zangrossi Jr Modification of chlordiazepoxide's behavioural and neurochemical effects by handling and plus-maze experience Eur. J. Pharmacol. 218 1992 9 14
65. S.E. File, H. Zangrossi Jr, M. Viana, and F.G. Graeff Trial 2 in the elevated plus maze: a different form of fear? Psychopharmacology 111 1993 491 494
66. S.E. File, H. Zangrossi, F.L. Sanders, and P.S. Mabbutt Raised corticosterone in the rat after exposure to the elevated plus maze Psychopharmacology 113 1994 543 546
67. S.E. File, L.E. Gonzalez, and R. Gallant Role of the basolateral nucleus of the amygdala in the formation of a phobia Neuropsychopharmacology 19 1998 397 405
68. S.E. File, L.E. Gonzalez, and R. Gallant Role of the dorsomedial hypothalamus in mediating the response to benzodiazepines on trial 2 in the elevated plus-maze test of anxiety Neuropsychopharmacology 21 1999 312 320
69. R. Frussa-Filho, and R.de.A. Ribeiro One-trial tolerance to the effects of chlordiazepoxide in the elevated plus-maze is not due to acquisition of a phobic avoidance of open arms during initial exposure Life Sci. 71 2002 519 525
70. L.E. Gonzalez, and S.E. File A five-minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus J. Neurosci. 17 1997 1505 1511
71. J.M. Gorman New molecular targets for antianxiety interventions. J. Clin. Psychiatry 64 Suppl. 3 2003 28 35
72. A.J. Gray, and N. McNaughton The Neuropsychology of Anxiety second ed 2000 Oxford University Press New York pp. 72-82
73. S. Green, and H. Hodges Animal models of anxiety P. Willner Behavioural Models in Psychopharmacology 1991 CUP Cambridge 21 29
74. G. Griebel Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82 1999 1 61
75. G. Griebel, J.L. Moreau, F. Jenck, J.R. Martin, and R. Misslin Some critical determinants of the behaviour of rats in the elevated plus-maze Behav. Proc. 29 1993 37 48
76. G. Griebel, R.J. Rodgers, G. Perrault, and D.J. Sanger Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test Pharmacol. Biochem. Behav. 57 1997 817 827
77. S.L. Handley, and S. Mithani Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour Naunyn Schmiedebergs Arch. Pharmacol. 327 1984 1 5
78. S.L. Handley, and J.W. McBlane 5HT drugs in animal models of anxiety Psychopharmacology 112 1993 13 20
79. M. Hascoet, M. Bourin, and A. Couetoux du Tertre Influence of prior experience on mice behavior using the four-plate test Pharmacol. Biochem. Behav. 58 1997 1131 1138
80. S. Hogg A review of the validity and variability of the elevated plus-maze as an animal model of anxiety Pharmacol. Biochem. Behav. 54 1996 21 30
81. C. Holden Psychiatric drugs. Excited by glutamate Science 300 2003 1866 1868
82. A. Holmes Targeted gene mutation approaches to the study of anxiety-like behavior in mice Neurosci. Biobehav. Rev. 25 2001 261 273
83. A. Holmes, and R.J. Rodgers Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for qualitative shift in emotional state? Pharmacol. Biochem. Behav. 60 1998 473 488
84. A. Holmes, and R.J. Rodgers Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze Neurosci. Biobehav. Rev. 23 1999 971 980
85. A. Holmes, J.P. Iles, S.J. Mayell, and R.J. Rodgers Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test Behav. Brain Res. 122 2001 159 167
86. S.D. Hood, S.V. Argyropoulos, and D.J. Nutt New directions in the treatment of anxiety disorders Expert Opin. Ther. Patents 13 2003 401 423
87. J.T. Imhof, Z.M. Coelho, M.L. Schmitt, G.S. Morato, and A.P. Carobrez Influence of gender and age on performance of rats in the elevated plus maze apparatus Behav. Brain Res. 56 1993 177 180
88. M.C. Jardim, and F.S. Guimaraes GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus Pharmacol. Biochem. Behav. 69 2001 579 584
89. D.C. Javitt Glutamate receptors as therapeutic targets Mol. Psychiatry 9 2004 984 997
90. A.L. Jinks, and I.S. McGregor Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat Brain Res. 772 1997 181 190
91. A.L. Johnston, and S.E. File Sex differences in animal tests of anxiety Physiol. Behav. 49 1991 245 250
92. N. Jones, and S.M. King Influence of circadian phase and test illumination on pre-clinical models of anxiety Physiol. Behav. 72 2001 99 106
93. J.M. Kent, S.J. Mathew, and J.M. Gorman Molecular targets in the treatment of anxiety Biol. Psychiatry 52 2002 1008 1030
94. L. Lacroix, S. Spinelli, C.A. Heidbreder, and J. Feldon Differential role of the medial and lateral prefrontal cortices in fear and anxiety Behav. Neurosci. 114 2000 1119 1130
95. Y. Lamberty, and A.J. Gower Arm width and brightness modulation of spontaneous behaviour of two strains of mice tested in the elevated plus-maze Physiol. Behav. 59 1996 439 444
96. M.R. Lamprea, F.P. Cardenas, R. Silveira, S. Morato, and T.J. Walsh Dissociation of memory and anxiety in a repeated elevated plus maze paradigm: forebrain cholinergic mechanisms Behav. Brain Res. 117 2000 97 105
97. I.P. Lapin Only controls: effect of handling, sham injection, and intraperitoneal injection of saline on behavior of mice in an elevated plus-maze J. Pharmacol. Toxicol. Methods 34 1995 73 77
98. C. Lee, and R.J. Rodgers Antinociceptive effects of plus-maze exposure: Influence of opiate receptor manipulations Psychopharmacology 102 1990 507 513
99. R.G. Lister The use of a plus-maze to measure anxiety in the mouse Psychopharmacology 92 1987 180 185
100. R. Lister Ethologically-based animal models of anxiety disorders Pharmacol. Ther. 46 1990 321 340
101. F.K. Marcondes, K.J. Miguel, L.L. Melo, and R.C. Spadari-Bratfisch Estrous cycle influences the response of female rats in the elevated plus-maze test Physiol. Behav. 74 2001 435 440
102. J.C. Martínez, F. Cardenas, M. Lamprea, and S. Morato The role of vision and proprioception in the aversion of rats to the open arms of an elevated plus-maze Behav. Process 60 2002 15 26
103. D. McFarland The Oxford Companion to Animal Behaviour 1987 Oxford University Press New York
104. I.S. McGregor, and R.A. Dielenberg Differential anxiolytic efficacy of a benzodiazepine on first versus second exposure to a predatory odor in rats Psychopharmacology 147 1999 174 181
105. N. McNaughton, and R.G. Morris Chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats Behav. Brain Res. 24 1987 39 46
106. S. Mechiel Korte, and S.F. De Boer A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze Eur. J. Pharmacol. 463 2003 163 175
107. J. Menard, and D. Treit Effects of centrally administered anxiolytic compounds in animal models of anxiety Neurosci. Biobehav. Rev. 23 1999 591 613
108. M.J. Millan The neurobiology and control of anxious states Prog. Neurobiol. 70 2003 83 244
109. S. Mora, N. Dussaubat, and G. Diaz-Veliz Effects of the estrous cycle and ovarian hormones on behavioral indices of anxiety in female rats Psychoneuroendocrinology 21 1996 609 620
110. S. Morato, and P. Castrechini Effects of floor surface and environmental illumination on exploratory activity in the elevated plus-maze Braz. J. Med. Biol. Res. 22 1989 707 710
111. J.I. Morgan, and T. Curran Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun Annu. Rev. Neurosci. 14 1991 421 451
112. P.C. Moser An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone Psychopharmacology 99 1989 48 53
113. R.L. Nunes-de-Souza, A. Canto-de-Souza, and R.J. Rodgers Effects of intra-hippocampal infusion of WAY-100635 on plus-maze behavior in mice. Influence of site of injection and prior test experience Brain Res. 927 2002 87 96
114. D.J. Nutt, and A.L. Malizia New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder Br. J. Psychiatry 179 2001 390 396
115. F. Ohl Testing for anxiety Clin. Neurosci. Res. 3 2003 233 238
116. C.M. Padovan, and F.S. Guimaraes Restraint-induced hypoactivity in an elevated plus-maze Braz. J. Med. Biol. Res. 33 2000 79 83
117. S. Pellow, P. Chopin, S.E. File, and M. Briley Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J. Neurosci. Methods 14 1985 149 167
118. J.K. Pereira, R.J. Vieira, C.T. Konishi, R.A. Ribeiro, and R. Frussa-Filho The phenomenon of 'one trial tolerance' to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze is abolished by the introduction of a motivational conflict situation Life Sci. 65 1999 101 107
119. A. Ramos, O. Berton, P. Mormede, and F. Chaouloff A multiple-test study of anxiety-related behaviours in six inbred rat strains Behav. Brain Res. 85 1997 57 69
120. D.D. Rasmussen, D.R. Mitton, J. Green, and S. Puchalski Chronic daily ethanol and withdrawal: 2. Behavioral changes during prolonged abstinence Alcohol Clin. Exp. Res. 25 2001 999 1005
121. A. Rex, H. Fink, and C.A. Marsden Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze Neuropharmacology 33 1994 559 565
122. R.J. Rodgers Animal models of 'anxiety': where next? Behav. Pharmacol. 8 1997 477 496
123. R.J. Rodgers, and J.C. Cole Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors Physiol. Behav. 53 1993 383 388
124. R.J. Rodgers, and J.C. Cole Influence of social isolation, gender, strain, and prior novelty on plus-maze behaviour in mice Physiol. Behav. 54 1993 729 736
125. R.J. Rodgers, and J.C. Cole The elevated plus-maze: pharmacology, methodology and ethology S.J. Cooper C.A. Hendrie Ethology and Psychopharmacology 1994 Wiley Chichester 9 44
126. R.J. Rodgers, and A. Dalvi Anxiety, defence and the elevated plus-maze Neurosci. Biobehav. Rev. 21 1997 801 810
127. R.J. Rodgers, and N.J. Johnson Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety Pharmacol. Biochem. Behav. 52 1995 297 303
128. R.J. Rodgers, and J.K. Shepherd Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice Psychopharmacology 113 1993 237 242
129. R.J. Rodgers, C. Lee, and J.K. Shepherd Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience Psychopharmacology 106 1992 102 110
130. R.J. Rodgers, N.J.T. Johnson, J.C. Cole, C.V. Dewar, G.R. Kidd, and P.H. Kimpson Plus-maze retest profile in mice: importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade Pharmacol. Biochem. Behav. 54 1996 41 50
131. R.J. Rodgers, B.J. Cao, A. Dalvi, and A. Holmes Animal models of anxiety: an ethological perspective Braz. J. Med. Biol. Res. 30 1997 289 304
132. R.J. Rodgers, J. Haller, A. Holmes, J. Halasz, T.J. Walton, and P.F. Brain Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice Physiol. Behav. 68 1999 47 53
133. R.J. Rodgers, B. Davies, and R. Shore Absence of anxiolytic response to chlordiazepoxide in two common background strains exposed to the elevated plus-maze: importance and implications of behavioural baseline Genes Brain Behav. 1 2002 242 251
134. V. Roy, and P. Chapillon Further evidences that risk assessment and object exploration behaviours are useful to evaluate emotional reactivity in rodents Behav. Brain Res. 154 2004 439 448
135. C. Salum, A.C. Roque-da-Silva, and S. Morato Conflict as a determinant of rat behavior in three types of elevated plus-maze Behav. Process 63 2003 87 93
136. U. Schmitt, and C. Hiemke Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling Pharmacol. Biochem. Behav. 59 1998 807 811
137. J. Setem, A.P. Pinheiro, V.A. Motta, S. Morato, and A.P. Cruz Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze Pharmacol. Biochem. Behav. 62 1999 515 521
138. J.K. Shepherd, S.S. Grewal, A. Fletcher, D.J. Bill, and C.T. Dourish Behavioural and pharmacological characterisation of the elevated zero-maze as an animal model of anxiety Psychopharmacology 116 1994 56 64
139. M.C. Silveira, G. Sandner, and F.G. Graeff Induction of Fos immunoreactivity in the brain by exposure to the elevated plus-maze Behav. Brain Res. 56 1993 115 118
140. N. Singewald, and T. Sharp Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry Neuroscience 98 2000 759 770
141. H.L. Steenbergen, R.P. Heinsbroek, A. Van Hest, and N.E. Van de Poll Sex-dependent effects of inescapable shock administration on shuttlebox-escape performance and elevated plus-maze behavior Physiol. Behav. 48 1990 571 576
142. C. Torres, and M.D. Escarabajal Validation of a behavioral recording automated system in the elevated plus-maze test Life Sci. 70 2002 1751 1762
143. D. Treit, and J. Menard Dissociations among the anxiolytic effects of septal, hippocampal, and amygdaloid lesions Behav. Neurosci. 111 1997 653 658
144. D. Treit, J. Menard, and C. Royan Anxiogenic stimuli in the elevated plus-maze Pharmacol. Biochem. Behav. 44 1993 463 469
145. R. Trullas, and P. Skolnick Differences in fear motivated behaviors among inbred mouse strains Psychopharmacology 111 1993 323 331
146. G.B. Varty, C.A. Morgan, M.E. Cohen-Williams, V.L. Coffin, and G.J. Carey The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation Neuropsychopharmacology 27 2002 357 370
147. M. Vaswani, F.K. Linda, and S. Ramesh Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 85 102
148. V. Voikar, S. Koks, E. Vasar, and H. Rauvala Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies Physiol. Behav. 72 2001 271 281
149. A. Zanotti, L. Valzelli, and G. Toffano Reversal of scopolamine-induced amnesia by phosphatidylserine in rats Psychopharmacology 90 1986 274 275
150. Web of Science. According to the search performed in July 2005, using the entering expression "elevated plus-maze", at the site http://isi9.isiknowledge.com.
151. S.M. Weiss, G. Wadsworth, A. Fletcher, and C.T. Dourish Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety Neurosci. Biobehav. Rev. 23 1998 265 271
152. S.M. Weiss, S. Lightowler, K.J. Stanhope, G.A. Kennett, and C.T. Dourish Measurement of anxiety in transgenic mice Rev. Neurosci. 11 2000 59 74
153. P.C. Yannielli, B.I. Kanterewicz, and D.P. Cardinali Daily rhythms in spontaneous and diazepam-induced anxiolysis in Syrian hamsters Pharmacol. Biochem. Behav. 54 1996 651 656